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Congenital bilateral absence of the vas deferens (CBAVD)
is found in 1–2% of infertile males and in most male cystic
fibrosis (CF) patients. CF and some of the CBAVD cases
were found to share the same genetic background. In this
study, 21 males with CBAVD had extensive physical and
laboratory testing for symptoms of CF. Possible defective
cellular chloride transport was measured by interstitial
current measurement of rectal suction biopsies. Cystic
fibrosis transmembrane conductance regulator (CFTR)
gene mutation analysis was performed for 10 common
CFTR mutations. CF-related symptoms were found in six
men. On laboratory testing slightly abnormal liver and
pancreatic function was found in seven patients. The sweat
test was found to be abnormal in four patients; interstitial
current measurement showed defective chloride excretion
in 11 patients. CFTR gene mutations were found in 66%
of the patients: eight were compound heterozygotes; in six,
only one common mutation could be detected. The 5T
allele in one copy of intron 8 was found in four men.
CBAVD appears to be a heterogeneous clinical and genetic
condition. A CFTR gene mutation was found in both copies
of the allele or interstitial current measurement showed
defective chloride excretion in 14/21 cases. Genetic counsel-
ling is clearly indicated for couples seeking pregnancy
through epididymal or testicular sperm aspiration and
intracytoplasmic sperm injection.
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Introduction
Congenital absence of the vas deferens (CBAVD), due to
bilateral regression of the mesonephric duct, occurs in 1–2%
of infertile males and in 6% of azoospermic men (Oates and
Amos, 1994). Clinical symptoms of CBAVD are bilateral non-
palpable vas deferens, absence of the distal part of the
epididymis and hypoplasia of the vesicula seminalis. Azoosper-
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mia with low semen plasma volume (,1.5 ml) and low
pH (,7.5) is consistently found. Testis volume and serum
gonadotrophins are usually normal. Testicular biopsy shows
normal or slightly defective spermatogenesis. Viable spermato-
zoa can be harvested from the epididymis by micropuncture
(MESA) and pregnancy can be obtained by in-vitro fertilization
(IVF) or intracytoplasmic sperm injection (ICSI; Silber
et al., 1994).
The aetiology of CBAVD is unknown. Most male cystic
fibrosis (CF) patients have CBAVD, and it was suggested that
CBAVD represents an incomplete form of CF (Holsclaw
et al., 1971). Since the identification of the cystic fibrosis
transmembrane regulator (CFTR) gene (Riordan et al., 1989),
mutations have been found in 62% of cases of CBAVD
(Patricio et al., 1993; Mercier et al., 1995; De Braekeleer and
Ferec, 1996).
CBAVD patients have been reported to carry two, one or
no CFTR gene mutations, one of them being ∆F508, the most
frequent CF mutation. Recently, the R117H mutation, a rare
mutation in CF patients, was found to occur frequently in
CBAVD patients (Gervais et al., 1993). Furthermore, the 5T
variant of the polypyrimidine stretch in intron 8, which is
thought to influence splicing, was shown to occur more
frequently in CBAVD as compared to controls (Chu et al.,
1993; Chillon et al., 1995). In cases where CBAVD is
associated with urogenital malformation, CFTR gene mutations
appear to be absent, suggesting a different aetiology (Dumur
et al., 1996).
The aim of this study was to investigate whether patients
with CBAVD have other CF related non-genital manifestations,
and if so, how to improve genetic counselling in case of
demand for MESA/ICSI treatment.
Materials and methods
Patients
This study was approved by the Hospital Medical Ethical committee
and by patients by written informed consent. Twenty-one infertile
patients with obstructive azoospermia due to bilateral absence of the
scrotal vas deferens were enrolled in the study. The diagnosis was
made by physical examination and confirmed by demonstration of
azoospermia with low semen plasma volume and low pH.
A medical history was obtained focused on symptoms common in
CF, such as rhino-sinusitis, nasal polyps, obstructive lung disease,
recurrent pulmonary infections, gastro-intestinal malabsorption, fat
intolerance, oily stools, cholelithiasis, liver dysfunction and intestinal
obstruction. Family history was documented for CF and other genetic
abnormalities.
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Figure 1. Interstitial current measurements of a rectal biopsy.
pos 5 positive, neg 5 negative. I 5 CF response, II 5 low
residual chloride secretion, III 5 high residual chloride secretion.
Physical examination
This included urogenital and pulmonary investigation and measure-
ment of weight, height and nutritional state. Pulmonary function tests
included forced vital capacity (FVC) and forced expiratory volume
in 1 s (FEV1). A chest X-ray was performed. The Shwachman score
was determined for all patients (Shwachman, 1990). Sonography of
the kidneys and transrectal ultrasound was performed to detect
urogenital malformations.
Laboratory testing
Laboratory testing included bacterial cultures in sputum, measure-
ments of gonadotrophins [luteinizing hormone (LH) and follicle
stimulating hormone (FSH)], liver function, serum glucose level and
faecal chymotrypsin. Bilateral sweat tests were performed and, in the
absence of normal values for adults, judged as abnormal if chloride
.50 mmol/l.
Electrophysiological study
Interstitial current measurement on rectal tissue were performed (Veeze
et al., 1994). Rectal suction biopsies were mounted in an Ussing
chamber with an exposed area of 1.13 mm2. Sodium channels were
blocked by adding amiloride (10–4 mol/l). Endogenous prostaglandin
synthesis that is possibly linked to cAMP-mediated chloride secretion
was inhibited by adding indomethacin (10–5 mol/l). Carbachol (10–4
mol/l) was added for cholinergic activation of chloride secretion.
In healthy controls, a carbachol-provoked change in interstitial
current measurement values was found (control, Figure 1). The inward
current in controls reflects transcellular chloride transport (serosa to
mucosa) through the Na–K–Cl co-transporter in the basolateral
membrane and the CFTR–chloride channel in the apical membrane.
In the majority of CF patients, a carbachol-induced outward current
response (type I negative, Figure 1) occurs. This reversed response
probably results from apical potassium secretion that is unmasked in
the case of absent or largely reduced chloride secretion.
In a subclass of CF patients, usually after a negative peak response,
a separate and small positive peak response was observed, the result
of low residual chloride secretion (type II, Figure 1). In another
subset of cases, a high residual chloride secretion was seen (type III,
Figure 1), due to chloride excretion by non-CFTR channels. The
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amount of residual chloride secretion appeared to be associated with
preserved pancreatic function and delayed presentation of the disease,
which was not exclusively determined by the CF genotype (Veeze
et al., 1994).
Interstitial current measurements are especially indicated in indi-
viduals with borderline or high normal sweat test results and an
inconclusive CFTR mutation analysis, who cannot otherwise be
distinguished from CF-carriers.
DNA analysis
DNA was isolated from peripheral leukocytes. CFTR mutation
analysis was performed for 10 mutations: we analysed for the
mutations R117H, A455E, ∆F508, 1717–1G→A, G542X, R553X,
R1162X, S1251N, W1282X, and N1303K. The length of the T-stretch
in intron 8 was determined (Kiesewetter et al., 1993). Only the allele
specific oligonucleotide for the identification of the 9 T-stretch was
changed into: 59-TGTGTG TTT TTT TTT AAC AG-39, using a
hybridization temperature of 37°C for all allele specific oligonucleo-
tides.
Results
Table I summarizes the abnormal physical and laboratory
findings. The history revealed nasal polyps/rhino-sinusitis (n 5
3), obstructive lung disease (n 5 1) and fatty stools (n 5 2).
Two patients had a positive family history for CF. Pulmonary
function was abnormal in one case with a history of pertussis
in childhood: on chest X-ray atelectasis and bronchiectasis
were found. The Shwachman score was abnormal in one (80)
and borderline (95) in another case.
High gamma-glutamyl transpeptidase, not related to alcohol
consumption, was found in six cases. Faecal chymotrypsin was
low in four cases, indicating exocrine pancreatic dysfunction. In
four cases, the sweat test was borderline by using strict criteria.
Interstitial current measurement showed either a typical CF
response (Figure 1, type I) (n 5 4), a low residual chloride
secretion (Figure 1, type II) (n 5 1) or a high residual secretion
(Figure 1, type III) (n 5 6). The test was found inconclusive
in one case and normal (Figure 1, control) in 10 patients.
CFTR gene analysis showed one or two mutations in 14/21
cases. In eight patients two different mutations (compound
heterozygosity) were found; in six patients only one mutation
could be identified. In seven cases, no common CFTR gene
mutation could be detected: four out of seven of these were
non-Caucasians. A 5T allele in one copy of the CFTR gene
was found in four cases, three times in combination with a
mutation in the other allele.
The ∆F508 mutation was found in eight patients, R117H in
six, A445E in three and 1717–1G→A and R553X both in one.
Three partners were found to have a single CFTR gene
mutation (R117H, R117H, ∆F508).
Discussion
The observation that the vas deferens is absent in almost all
male CF patients suggested that CBAVD is a primary genital
form of CF (Holsclaw et al., 1971). Following the identification
of the CFTR gene, CBAVD and CF were also often found to
share the same genetic background (Mercier et al., 1993;
Patricio et al., 1993). CFTR, the product of the CFTR gene,
CBAVD and cystic fibrosis
Table I. Summary of physical and laboratory findings in patients with CBAVD
Case no. Age History tests Laboratory Sweat ICM CFTR mutations T-stretch Remarks
(years) Cl–/Na1 test intron 8
1 36 NA NA 38/46 CF response (I) ∆F508/R117H 9/7 Non-Caucasian
2 27 Sinusitis/fat intol. Chymotr., 23/22 CF response (I) ∆F508/R117H 9/7 CF in family
3 33 CARA/oily stools Ggt.,Chymotr., 23/36 CF response (I) ∆F508/– 9/7
4 31 Pelvic re kidney NA 10/22 CF response (I) –/– 7/7
5 32 Sinusitis/nasal Chymotr., 50/52 CF low residual (II) A455E/– 9/5 Partner ∆dF508
polyps
6 38 NA NA 40/43 CF high residual (III) A445E/R117H 9/7
7 27 NA Ggt.,Chymotr., 28/44 CF high residual (III) R117H/R553X 7/7 Partner R117H
8 38 Nasal polyps NA 34/51 CF high residual (III) ∆F508/R117H 9/7 Pertussis
9 36 NA NA 58/70 CF high residual (III) ∆F508/– 9/5
10 31 NA Ggt. 54/70 CF high residual (III) ∆F508/– 9/5 Partner R117H
11 32 Maldescended Ggt. 16/34 CF high residual (III) –/– 9/7 Single kidney in family
testis
12 35 NA NA 14/21 Inconclusive ∆F508/– 9/7
13 29 NA NA 43/70 Normal response (IV) A455E/R117H 9/7
14 38 NA NA 32/55 Normal response (IV) R117H/1717–1→G→A 7/7
15 29 NA Ggt. 44/66 Normal response (IV) ∆F508/R117H 9/7
16 28 NA NA 42/48 Normal response (IV) R117H/– 7/7
17 36 NA NA 22/44 Normal response (IV) –/– 7/5 Non-Caucasian
18 34 NA NA 57/30 Normal response (IV) –/– 7/7 Non-Caucasian
19 39 NA NA 36/52 Normal response (IV) –/– 7/7 Non-Caucasian
20 31 NA NA 16/30 Normal response (IV) –/– 7/7 Non-Caucasian
21 34 NA NA 20/41 Normal response (IV) –/– 7/7
NA 5 no abnormalities, GgT 5 gamma glutamyl transpeptidase, Chymotr. 5 chymotrypsin, ICM 5 interstitial current measurement (see Figure 1), CFTR 5
cystic fibrosis transmembrane conductance regulator gene, –: none of 10 CF mutations, T-stretch 5 polypyrimidine (T) stretch intron 8.
Shwachman score was 95 in case 1 and 80 in case 8. Physical examination showed bronchiectasis in case 8 and hypogonadism in case 19.
a cell membrane protein of 1480 amino acids, regulates
transmembrane chloride transport. Over 750 mutations of the
CFTR gene have been reported, ∆F508 being the most frequent
mutation in CF patients. CF is an autosomal recessive disease;
a patient with CF receives two defective alleles. The carrier
risk in Caucasians is 1:25.
In CF, conductive chloride transport is defective in epithelial
tissues, resulting in viscous secretions associated with pulmon-
ary infections, malabsorption and intestinal obstruction. The
severity of the disease varies widely: homozygosity for the
∆F508 mutation was found to be associated with pancreatic
insufficiency, early manifestations, poor lung function and high
mortality (Kerem et al., 1990). Other mutations, like R117H,
are associated with a milder form of CF where conductive
chloride transport is defective, but not absent (Gervais et al.,
1993).
The CFTR gene mutations occur frequently in CBAVD
(Patricio et al., 1993; Oates and Amos, 1994; de Braekeleer
et al., 1996), but the molecular basis of CBAVD is not
completely understood. Mutations with a low frequency in
classic CF, such as R117H, were found to occur regularly in
CBAVD (Gervais et al., 1993). Homozygosity for ∆F508 or
compound heterozygosity for two severe mutations were not
found in cases of CBAVD. It has been suggested that CBAVD
patients are compound heterozygotes for a severe mutation on
one allele in combination with a mild CFTR gene mutation
on the other allele. In the majority of cases, however, only
one CFTR gene mutation could be detected in CBAVD.
Recently alterations in the non-coding regions of the gene,
such as the polypyrimidine stretch in intron 8, in combination
with a mutation in the other allele, were found to cause
abnormal levels of CFTR protein (Chu et al., 1993). Impaired
CFTR protein function may cause defective, but not absent
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chloride excretion, resulting in absence of the vas deferens,
but not in pulmonary or pancreatic insufficiency (Anguiano
et al., 1992). The epididymis may be more susceptible to
defective chloride transport, resulting in an early regression of
the mesonephric duct. In contrast, only 6% of CFTR protein
function is necessary for normal pancreatic function (Tizzano
et al., 1994). Also, the wide variability of symptoms related
to various combinations of CFTR mutations suggests a possible
role for unlinked genetic factors in the expression of these
mutations.
In this study, 21 patients with CBAVD were investigated
for non-genital manifestations of CF: in six patients mild CF
symptoms were present. Slightly abnormal liver and pancreatic
function were detected in seven, sweat tests showed high
levels of chloride in four patients. Electrophysiology of rectal
suction biopsies, not previously performed in CBAVD, showed
defective chloride excretion in 11 patients. Three of these
patients showed very low sweat test results, indicating different
tissue expression of impaired CFTR function.
CBAVD appears to be a heterogeneous clinical and genetic
condition: two CFTR gene mutations were detected in eight
patients, five of them showing CF characteristics on interstitial
current measurement. In these men the CBAVD might represent
a mild form of CF. Of the patients carrying a single CFTR
mutation, four also showed defective chloride excretion on
interstitial current measurement, suggesting mutations going
undetected with the current screening technology. So far, no
convincing evidence has been brought forward that the presence
of a single CFTR mutation (i.e. simple heterozygosity) has any
phenotypic consequences (Meschede et al., 1997). Therefore, in
the case of CBAVD and defective chloride excretion further
analysis of the CFTR gene is required to detect rare variant
mutations.
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In most cases of CBAVD, residual or normal chloride
excretion was found in combination with either an abnormal
sweat test or CFTR gene mutations. Only in five cases of
CBAVD no abnormalities could be found, four of these men
being non-Caucasians. These results suggest that there is a
wide spectrum of phenotypic expression of cystic fibrosis,
with pancreatic and pulmonary insufficiency at one end and
CBAVD at the other.
Since the introduction of microsurgical epididymal sperm
aspiration and intracytoplasmic sperm injection (Silber et al.,
1994) infertility due to CBAVD has been treated successfully,
resulting in ongoing pregnancy. Biological parenthood is now
a realistic option for males with CBAVD, producing ongoing
pregnancies in 20–30% of cases (Dohle et al., 1998).
For couples with CBAVD-related infertility CFTR mutation
analysis and genetic counselling of the patient and his partner
is essential before MESA/ICSI procedures are performed
(Pauer et al., 1997). Although the a priori carrier risk for a
CFTR gene mutations is only 3–4%, three partners of the male
CBAVD group had a single CFTR gene mutation. In these
cases the risk of offspring with a (mild or severe) form of CF
could be 50%.
As there is no straightforward relationship between the
genotype and the phenotype for most CFTR gene mutations,
genetic counselling in these situations is complex, as no precise
predictions on rare compound phenotypes of CF are possible.
Considering all the medical and psychological burdens of
MESA and ICSI procedures, followed by chorionic biopsy
for early prenatal diagnosis of CF, reproduction becomes
complicated for these couples. Pre-implantation screening of
embryos would be an alternative technique for prenatal dia-
gnosis, but does not solve all ethical problems. In case of a
CFTR mutation in the partner and no detectable mutation in
the CBAVD male, a positive interstitial current measurement
test in the patient will indicate rare variant alleles of the CF
gene. However, if no CFTR gene mutations are found in the
female partner, the risk of offspring with CF is at the most
1:400. Prenatal or preimplantation screening for CF is not
possible in these cases.
In conclusion, CBAVD appears to be a heterogeneous
condition with respect to CF symptoms, tissue expression of
defective chloride excretion and CFTR gene mutation analysis.
Only in a small subset of men with CBAVD could no
abnormalities be detected.
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